MCID: NTR004
MIFTS: 62

Neutropenia

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Endocrine diseases, Genetic diseases, Immune diseases, Infectious diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Neutropenia

Summaries for Neutropenia

MalaCards based summary : Neutropenia, also known as leukopenia, is related to poikiloderma with neutropenia and neutropenia, severe congenital, x-linked. An important gene associated with Neutropenia is ELANE (Elastase, Neutrophil Expressed), and among its related pathways/superpathways are JAK-STAT signaling pathway and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Cisplatin and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include breast, myeloid and neutrophil, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Neutropenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood.... more...

Related Diseases for Neutropenia

Diseases in the Neutropenia family:

Neutropenia, Chronic Familial Neutropenia, Severe Congenital, 1, Autosomal Dominant
Neutropenia, Severe Congenital, 3, Autosomal Recessive Neutropenia, Severe Congenital, 4, Autosomal Recessive
Neutropenia, Severe Congenital, 2, Autosomal Dominant Neutropenia, Severe Congenital, 5, Autosomal Recessive
Neutropenia, Severe Congenital, 6, Autosomal Recessive Neutropenia, Severe Congenital, 7, Autosomal Recessive
Neutropenia, Severe Congenital, 8, Autosomal Dominant Severe Congenital Neutropenia
Severe Congenital Neutropenia 1 Severe Congenital Neutropenia 7
Autosomal Dominant Severe Congenital Neutropenia Severe Congenital Neutropenia 2
Severe Congenital Neutropenia 5 Severe Congenital Neutropenia 3
Severe Congenital Neutropenia 6 Severe Congenital Neutropenia 8
Severe Congenital Neutropenia 4 Elane-Related Neutropenia
Acquired Neutropenia Autosomal Recessive Severe Congenital Neutropenia

Diseases related to Neutropenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 990)
# Related Disease Score Top Affiliating Genes
1 poikiloderma with neutropenia 33.1 USB1 G6PC3
2 neutropenia, severe congenital, x-linked 33.1 WAS ELANE
3 cyclic neutropenia 33.1 TAFAZZIN SLC37A4 JAGN1 IL3 HAX1 GFI1
4 severe congenital neutropenia 33.0 WAS VPS45 SRP54 JAGN1 IL3 HAX1
5 neutropenia, severe congenital, 3, autosomal recessive 33.0 JAGN1 IL3 HAX1 ELANE CSF3R CSF3
6 autosomal dominant severe congenital neutropenia 32.8 SRP54 GFI1 ELANE
7 idiopathic neutropenia 32.8 GFI1 CSF3R
8 felty syndrome 32.7 IL3 CSF3 CSF2
9 whim syndrome 32.5 HAX1 G6PC3 ELANE CSF3
10 autosomal recessive severe congenital neutropenia 32.3 HAX1 G6PC3 ELANE CSF3R
11 shwachman-diamond syndrome 1 32.3 SRP54 HAX1 GFI1 G6PC3 ELANE CSF3R
12 cohen syndrome 32.1 VPS45 VPS13B SLC37A4 JAGN1 HAX1 GFI1
13 leukemia, acute lymphoblastic 32.0 TPMT TOP1 IL3 CSF3R CSF3 CSF2
14 granulocytopenia 31.8 IL3 CSF3 CSF2
15 bacterial infectious disease 31.8 IL3 ELANE CSF3 CSF2
16 thiopurines, poor metabolism of, 1 31.6 UGT1A1 TPMT
17 leukemia, acute myeloid 31.5 TOP1 IL3 GFI1 CSF3R CSF3 CSF2
18 mucositis 31.4 IL3 CSF3 CSF2
19 aspergillosis 31.4 ELANE CSF3 CSF2
20 acute leukemia 31.4 TPMT IL3 CSF3R CSF3 CSF2
21 lymphoma, hodgkin, classic 31.3 IL3 CSF3 CSF2
22 myelodysplastic syndrome 31.3 TOP1 IL3 HAX1 GFI1 CSF3R CSF3
23 thrombocytopenia 31.2 WAS TOP1 IL3 CSF3 CSF2
24 aplastic anemia 31.0 TPMT IL3 CSF3R CSF3 CSF2
25 pancytopenia 30.9 TPMT IL3 G6PC3 CSF3 CSF2
26 ecthyma 30.8 HAX1 CSF3
27 mucormycosis 30.8 CSF3 CSF2
28 dyskeratosis congenita 30.7 USB1 HAX1 CSF3 CSF2
29 leukemia, chronic myeloid 30.6 IL3 ELANE CSF3R CSF3 CSF2
30 myelofibrosis 30.6 VPS45 IL3 CSF3R CSF3
31 gastroenteritis 30.6 IL3 CSF3 CSF2
32 thrombocytosis 30.4 IL3 CSF3 CSF2
33 chronic myelomonocytic leukemia 30.3 TOP1 CSF3R CSF3 CSF2
34 acute promyelocytic leukemia 30.3 IL3 ELANE CSF3R CSF3 CSF2
35 hematologic cancer 30.2 TOP1 IL3 CSF3 CSF2
36 leukocyte adhesion deficiency, type i 30.2 WAS SLC37A4 CSF3
37 myeloproliferative neoplasm 30.0 IL3 CSF3R CSF3 CSF2
38 retinitis pigmentosa and erythrocytic microcytosis 29.9 IL3 CSF3
39 hemorrhagic cystitis 29.7 TOP1 CSF3
40 barth syndrome 11.6
41 neutropenia, nonimmune chronic idiopathic, of adults 11.5
42 3-methylglutaconic aciduria, type vii 11.5
43 neutropenia, severe congenital, 5, autosomal recessive 11.5
44 neutropenia, severe congenital, 1, autosomal dominant 11.5
45 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 11.5
46 neutropenia, severe congenital, 7, autosomal recessive 11.5
47 neutropenia, severe congenital, 4, autosomal recessive 11.4
48 neutropenia, severe congenital, 8, autosomal dominant 11.4
49 neutropenia, severe congenital, 2, autosomal dominant 11.4
50 neutropenia, severe congenital, 6, autosomal recessive 11.4

Comorbidity relations with Neutropenia via Phenotypic Disease Network (PDN): (show all 48)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Leukemia Acute Megakaryocytic Leukemia
Agammaglobulinemia, X-Linked Anemia, Autoimmune Hemolytic
Bladder Cancer Bronchitis
Chronic Kidney Disease Colorectal Cancer
Decubitus Ulcer Deficiency Anemia
Esophageal Cancer Esophageal Candidiasis
Esophagitis Felty Syndrome
Female Breast Cancer Gastric Cancer
Granulomatosis with Polyangiitis Heart Disease
Hepatic Encephalopathy Hydronephrosis
Hypersplenism Hypothyroidism
Immune Deficiency Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Intestinal Obstruction Iron Deficiency Anemia
Leukemia, Chronic Lymphocytic Main Bronchus Cancer
Oral Candidiasis Ovarian Cancer
Paralytic Ileus Plasma Cell Neoplasm
Pneumocystosis Portal Hypertension
Postinflammatory Pulmonary Fibrosis Primary Thrombocytopenia
Protein-Energy Malnutrition Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2
Respiratory Failure Retinitis Pigmentosa and Erythrocytic Microcytosis
Rheumatoid Arthritis Sideroblastic Anemia
Systemic Lupus Erythematosus Waldenstroem's Macroglobulinemia

Graphical network of the top 20 diseases related to Neutropenia:



Diseases related to Neutropenia

Symptoms & Phenotypes for Neutropenia

GenomeRNAi Phenotypes related to Neutropenia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.96 USB1
2 Decreased viability GR00249-S 9.96 CLPB CSF2 CSF3R G6PC3 HAX1 TPMT
3 Decreased viability GR00381-A-1 9.96 JAGN1 USB1
4 Decreased viability GR00386-A-1 9.96 CLPB CSF3 JAGN1 SLC37A4 SRP54 TOP1
5 Decreased viability GR00402-S-2 9.96 G6PC3 IL3 SRP54 VPS45
6 Increased the percentage of infected cells GR00402-S-1 8.32 TOP1

MGI Mouse Phenotypes related to Neutropenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CSF2 CSF3 CSF3R ELANE G6PC3 GFI1
2 immune system MP:0005387 9.36 CSF2 CSF3 CSF3R ELANE G6PC3 GFI1

Drugs & Therapeutics for Neutropenia

Drugs for Neutropenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 383)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
2
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
3
Etoposide Approved Phase 4 33419-42-0 36462
4
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
7
Ceftazidime Approved Phase 4 78439-06-2, 72558-82-8 5481173
8
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
9
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
10
Teicoplanin Approved, Investigational Phase 4 61036-62-2
11
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
Sulfamethoxazole Approved Phase 4 723-46-6 5329
14
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
15
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
16
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
17
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
18
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
19
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
20
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
21
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
22
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130 64778
23
Tazobactam Approved Phase 4 89786-04-9 123630
24
Piperacillin Approved Phase 4 66258-76-2 43672
25
Abatacept Approved Phase 4 332348-12-6 10237
26
Ofloxacin Approved Phase 4 82419-36-1 4583
27
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
28
Ixazomib Approved, Investigational Phase 4 1072833-77-2
29
Lenalidomide Approved Phase 4 191732-72-6 216326
30
Daratumumab Approved Phase 4 945721-28-8
31
Bortezomib Approved, Investigational Phase 4 179324-69-7 93860 387447
32
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
33
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
34
Lenograstim Approved, Investigational Phase 4 135968-09-1
35
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
36
Ribavirin Approved Phase 4 36791-04-5 37542
37
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
38
Molgramostim Investigational Phase 4 99283-10-0
39 Etoposide phosphate Phase 4
40 Hormone Antagonists Phase 4
41 Hormones Phase 4
42 glucocorticoids Phase 4
43 Anti-Inflammatory Agents Phase 4
44 Cytochrome P-450 Enzyme Inhibitors Phase 4
45 Folic Acid Antagonists Phase 4
46 Antineoplastic Agents, Hormonal Phase 4
47 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
48 Antimalarials Phase 4
49 Cilastatin, Imipenem Drug Combination Phase 4
50
protease inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 438)
# Name Status NCT ID Phase Drugs
1 G-CSF (Filgrastim) or Pegfilgrastim Secondary Prophylaxis In The Adjuvant Chemotherapy Of Early Breast Cancer Unknown status NCT00030758 Phase 4
2 Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
3 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
4 Long-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients: A Prospective Cohort Study Unknown status NCT03793205 Phase 4 Long-acting G-CSF;Short-acting G-CSF
5 Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
6 Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
7 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
8 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
9 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
10 Validation of Central Venous (Port A Cath®) Blood Draws for Ciprofloxacin Pharmacokinetic Research in Patients Under Treatment for Childhood Cancer Unknown status NCT02967341 Phase 4
11 Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients Completed NCT00454272 Phase 4 Teicoplanin;Vancomycin
12 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole
13 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection Completed NCT01401010 Phase 4 Doripenem;doripenem
14 Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil Completed NCT04187755 Phase 4 Ceftazidime Injection;Cefepime Injection
15 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With Fever of Unknown Origin: a Randomized Multicenter Non-inferiority Trial. Completed NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
16 Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
17 A Multi-Centre Study to Compare Granulocyte-colony Stimulating Factors to Antibiotics for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induced Febrile Neutropenia REaCT-TC2 Completed NCT02816112 Phase 4 Ciprofloxacin;Neupogen
18 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
19 A Multi Centre Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (REaCT-G2) Completed NCT02816164 Phase 4 Neupogen
20 Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units Completed NCT00709358 Phase 4
21 Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Following Administration by 4-hour Infusion and Bolus Injection. Completed NCT02213783 Phase 4 Imipenem;Imipenem
22 Randomized Open Label Clinical Trial Directed to Optimize the Duration of Empirical Antimicrobial Therapy in Haematologic Patients With Febrile Neutropenia Completed NCT01581333 Phase 4 Empirical antimicrobial treatment discontinuation;Standard empirical antimicrobial treatment discontinuation
23 Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Completed NCT01198236 Phase 4 Itraconazole
24 A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy Completed NCT00125723 Phase 4
25 Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber Completed NCT00257790 Phase 4 Tobramycin once a day
26 A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
27 Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions Completed NCT02621905 Phase 4 Sporanox;Lozanoc
28 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
29 A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
30 The Multi-center, Open-label,Randomized Comparison Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
31 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
32 A Multi-center, Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805205 Phase 4 PEG-rhG-CSF
33 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
34 Study on the Efficacy and Safety of 4.5mg Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer Completed NCT04009941 Phase 4 PEG-rhG-CSF
35 Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia Completed NCT02173262 Phase 4 G-CSF;Ciprofloxacin
36 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
37 A Pilot Study of Granulocyte Colony-Stimulating Factor Starting at 24 Hours vs 72 Hours in Pediatric Oncology Patients Recruiting NCT03823950 Phase 4 Granulocyte Colony-Stimulating Factor
38 Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE) Recruiting NCT04233996 Phase 4 Piperacillin-Tazobactam 4 g-0.5 g;Cefepime 2000 mg;Meropenem 1000 mg
39 Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma Recruiting NCT04083079 Phase 4 PEG-rhG-CSF;rhG-CSF
40 Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial Recruiting NCT03227419 Phase 4 Tocilizumab Prefilled Syringe;Abatacept Prefilled Syringe
41 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
42 Injection Time Trial of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in Preventing Bone Marrow Suppression and/or Febrile Neutropenia (FN) During Breast Cancer Chemotherapy Not yet recruiting NCT04477616 Phase 4 PEG-rhG-CSF
43 A Randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated With Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected With HIV. Terminated NCT00194857 Phase 4 erythropoietin, GCSF
44 Phase III Study of 3 Sequential Doses (10 mg/kg, 5 mg/kg, and 5 mg/kg) vs 3 mg/kg/Day of AmBisome® in the Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics Terminated NCT00421187 Phase 4 Liposomal amphotericin B (AmBisome®);Liposomal amphotericin B (AmBisome®)
45 Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia Terminated NCT01859637 Phase 4
46 Subcutaneous (SC) vs. Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients: Randomized Controlled Trial Terminated NCT01222819 Phase 4 filgrastim
47 The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT" Terminated NCT00190463 Phase 4 Amphotericin B
48 Pegfilgrastim on Day +3 Compared to Day +1 for Patients With Refractory or Relapsed Aggressive Lymphoma Receiving Salvage Chemotherapy - a Randomized Controlled Trial Unknown status NCT02238873 Phase 3 Pegfilgrastim
49 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
50 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin

Search NIH Clinical Center for Neutropenia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Ciprofloxacin
Filgrastim
FILGRASTIM-SNDZ
Immunoglobulins, Intravenous
Itraconazole
pegfilgrastim
sargramostim

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neutropenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: neutropenia

Genetic Tests for Neutropenia

Genetic tests related to Neutropenia:

# Genetic test Affiliating Genes
1 Neutropenia 29

Anatomical Context for Neutropenia

MalaCards organs/tissues related to Neutropenia:

40
Breast, Myeloid, Neutrophil, Bone Marrow, Prostate, Bone, Lung

Publications for Neutropenia

Articles related to Neutropenia:

(show top 50) (show all 40262)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
2
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. 61 54
20175767 2010
3
Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected]. 54 61
19912214 2010
4
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. 54 61
20066544 2010
5
Circadian rhythm of neutrophil counts and granulocyte macrophage-colony stimulating factor (GM-CSF) under clozapine treatment: a case report. 54 61
19396726 2010
6
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. 54 61
19786849 2010
7
Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? 54 61
20136357 2010
8
Genetic insights into congenital neutropenia. 54 61
19440858 2010
9
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. 54 61
19932054 2010
10
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. 61 54
20068078 2010
11
Which role for rituximab in hairy cell leukemia? Reflections on six cases. 61 54
20051682 2010
12
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. 61 54
20021291 2010
13
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. 54 61
19297346 2010
14
Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. 61 54
19699815 2009
15
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. 61 54
19608554 2009
16
An outbreak of Crimean-Congo hemorrhagic fever in western Anatolia, Turkey. 61 54
19409826 2009
17
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. 61 54
19916175 2009
18
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. 54 61
19556318 2009
19
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. 61 54
19696793 2009
20
Prospective study of Chikungunya virus acute infection in the Island of La Réunion during the 2005-2006 outbreak. 61 54
19893613 2009
21
G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. 54 61
19794089 2009
22
A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. 61 54
19770418 2009
23
SBDS expression and localization at the mitotic spindle in human myeloid progenitors. 61 54
19759903 2009
24
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. 54 61
19756005 2009
25
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. 61 54
19223932 2009
26
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. 54 61
19457938 2009
27
Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. 54 61
19446318 2009
28
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. 61 54
19513514 2009
29
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI]. 61 54
19620808 2009
30
[Allelic variants of TPMT and the risk of leucopenia and neutropenia in patients treated for acute leukaemia]. 54 61
20081263 2009
31
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. 54 61
19604089 2009
32
Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. 54 61
19682195 2009
33
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. 61 54
19707503 2009
34
Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. 54 61
19200137 2009
35
Complement factors C3a and C5a have distinct hemodynamic effects in the rat. 61 54
19285573 2009
36
Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. 54 61
19435433 2009
37
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 61 54
19438482 2009
38
XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. 61 54
19404210 2009
39
A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-64Cu. 54 61
19372473 2009
40
A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. 61 54
19261493 2009
41
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. 54 61
19450125 2009
42
Neutropenia in congenital nephrotic syndrome of the Finnish type: role of urinary ceruloplasmin loss. 54 61
19423745 2009
43
Ela2 mutations and clinical manifestations in familial congenital neutropenia. 61 54
19415009 2009
44
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases. 54 61
19151787 2009
45
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). 61 54
19242368 2009
46
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. 61 54
19390945 2009
47
Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. 54 61
19454236 2009
48
Shwachman-Diamond syndrome neutrophils have altered chemoattractant-induced F-actin polymerization and polarization characteristics. 54 61
19211642 2009
49
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. 61 54
19347726 2009
50
[Autoimmune thrombocytopenia, neutropenia and hemolysis]. 54 61
19225748 2009

Variations for Neutropenia

ClinVar genetic disease variations for Neutropenia:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 VPS13B NM_017890.4(VPS13B):c.4620del (p.Ser1541fs) Deletion Pathogenic 374163 rs1057518939 GRCh37: 8:100523652-100523652
GRCh38: 8:99511424-99511424
2 VPS13B NM_017890.4(VPS13B):c.11314C>T (p.Gln3772Ter) SNV Pathogenic 56635 rs386834061 GRCh37: 8:100880540-100880540
GRCh38: 8:99868312-99868312
3 overlap with 47 genes GRCh37/hg19 22q11.21(chr22:18894835-21505417) copy number loss Pathogenic 523274 GRCh37: 22:18894835-21505417
GRCh38:
4 ELANE NM_001972.4(ELANE):c.597+5G>A SNV Pathogenic 245598 rs879253882 GRCh37: 19:855799-855799
GRCh38: 19:855799-855799
5 SLC37A4 NM_001164278.2(SLC37A4):c.81T>A (p.Asn27Lys) SNV Likely pathogenic 68290 rs193302889 GRCh37: 11:118899999-118899999
GRCh38: 11:119029289-119029289
6 HAX1 NM_006118.4(HAX1):c.182T>G (p.Phe61Cys) SNV Likely pathogenic 812887 rs146452018 GRCh37: 1:154245940-154245940
GRCh38: 1:154273464-154273464
7 VPS16 NM_022575.4(VPS16):c.540G>T (p.Trp180Cys) SNV Uncertain significance 932238 GRCh37: 20:2841419-2841419
GRCh38: 20:2860773-2860773
8 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu) SNV Uncertain significance 598996 rs1558697792 GRCh37: 2:31602803-31602803
GRCh38: 2:31379937-31379937
9 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His) SNV Uncertain significance 335760 rs143981573 GRCh37: 2:31562482-31562482
GRCh38: 2:31339616-31339616

Expression for Neutropenia

Search GEO for disease gene expression data for Neutropenia.

Pathways for Neutropenia

GO Terms for Neutropenia

Biological processes related to Neutropenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.73 IL3 CSF3R CSF3 CSF2
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.58 IL3 HAX1 CSF3
3 positive regulation of actin cytoskeleton reorganization GO:2000251 9.46 HAX1 CSF3
4 regulation of myeloid cell differentiation GO:0045637 9.37 CSF3R CSF2
5 neutrophil chemotaxis GO:0030593 9.33 SRP54 SLC37A4 CSF3R
6 negative regulation of chemokine production GO:0032682 9.32 SLC37A4 ELANE
7 granulocyte differentiation GO:0030851 9.26 SRP54 CSF3
8 glucose-6-phosphate transport GO:0015760 8.96 SLC37A4 G6PC3
9 neutrophil differentiation GO:0030223 8.62 JAGN1 CSF2

Sources for Neutropenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....